Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.45 is 105% below its 5-year average of -1.20, near the low end of its 5-year range (-2.45–-0.83).
43.70% below its 12-month average of -1.70.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.70.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T11:56:03.645Z. Historical observations retain their original dates. Historical series through 2019-03-29.
EARNINGS PER SHARE (EPS)
-2.45
EARNINGS PER SHARE (EPS) AVG TTM
-1.70
EARNINGS PER SHARE (EPS) AVG 3Y
-1.35
EARNINGS PER SHARE (EPS) AVG 5Y
-1.20
EARNINGS PER SHARE (EPS) AVG 10Y
-2.88
EARNINGS PER SHARE (EPS) AVG 15Y
-3.39
EARNINGS PER SHARE (EPS) AVG 20Y
-24.67
CURRENT VS TTM AVG
-43.70%
CURRENT VS 3Y AVG
-80.81%
CURRENT VS 5Y AVG
-105.02%
CURRENT VS 10Y AVG
+14.80%
CURRENT VS 15Y AVG
+27.80%
CURRENT VS 20Y AVG
+90.07%
Capricor Therapeutics, Inc.
Market Cap
$447.43M
Earnings Per Share (EPS)
-2.45
TTM Avg
-1.70
3Y Avg
-1.35
5Y Avg
-1.20
Market Cap
$450.64M
Earnings Per Share (EPS)
0.55
TTM Avg
-3.62
3Y Avg
-10.86
5Y Avg
-15.74
Market Cap
$453.70M
Earnings Per Share (EPS)
-0.72
TTM Avg
-0.65
3Y Avg
-0.60
5Y Avg
-0.64
Market Cap
$428.16M
Earnings Per Share (EPS)
-0.75
TTM Avg
-2.34
3Y Avg
-2.48
5Y Avg
-2.46
Market Cap
$471.57M
Earnings Per Share (EPS)
-0.04
TTM Avg
-0.10
3Y Avg
-0.16
5Y Avg
-0.22
Market Cap
$416.68M
Earnings Per Share (EPS)
-3.33
TTM Avg
-2.70
3Y Avg
-1.54
5Y Avg
-2.91
Market Cap
$478.54M
Earnings Per Share (EPS)
-1.73
TTM Avg
-1.90
3Y Avg
-1.16
5Y Avg
-1.16
Market Cap
$415.93M
Earnings Per Share (EPS)
-1.36
TTM Avg
-1.81
3Y Avg
-2.62
5Y Avg
-2.62
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Capricor Therapeutics, Inc. (CAPR) | $447.43M | -2.45 | -1.70 | -1.35 | -1.20 |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | 0.55 | -3.62 | -10.86 | -15.74 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | -0.72 | -0.65 | -0.60 | -0.64 |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | -0.75 | -2.34 | -2.48 | -2.46 |
| NRC Health (NRC)vs › | $468.31M | 0.25 | 0.79 | 1.03 | 1.18 |
| Cerus Corporation (CERS)vs › | $471.57M | -0.04 | -0.10 | -0.16 | -0.22 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | -3.33 | -2.70 | -1.54 | -2.91 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -1.73 | -1.90 | -1.16 | -1.16 |
| Carlsmed, Inc. (CARL)vs › | $415.93M | -1.36 | -1.81 | -2.62 | -2.62 |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 0.16 | -2.02 | -3.99 | -3.80 |
Trailing EPS (TTM)
$-2.45
Forward EPS (Est.)
$-1.54
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.26 |
| 2024-12-31 | -1.15 |
| 2023-12-31 | -0.83 |
| 2022-12-31 | -1.18 |
| 2021-12-31 | -0.87 |
| 2020-12-31 | -0.88 |
| 2019-12-31 | -2.06 |
| 2018-12-31 | -5.17 |
| 2017-12-31 | 1.00 |
| 2016-12-31 | -10.14 |
| 2015-12-31 | -8.09 |
| 2014-12-31 | -5.31 |
| 2013-12-31 | -8.47 |
| 2012-12-31 | -2.10 |
| 2011-12-31 | -65.43 |
| 2010-12-31 | -93.75 |
| 2009-12-31 | -154.56 |
| 2008-12-31 | -272.15 |
| 2007-12-31 | -304.06 |
| 2006-12-31 | -95.00 |
| 2005-12-31 | -12.49 |
| 2004-12-31 | -11.97 |
| 2003-12-31 | -10.70 |
| 2002-12-31 | -10.32 |
| 2001-12-31 | -14.77 |
| 2000-12-31 | -26.56 |
| 1999-12-31 | 0.00 |
